Mireia Margelí (Mireia Margeli Vila)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 7

Top Topics

Replacement Therapy

Peritoneal Dialysis

Epidermal Growth Factor Receptor

Small Cell Lung Cancer

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Angel L Guerrero-Zotano, Stefania Belli, Christoph C Zielinski, Juan Miguel Gil-Gil, Antonio Fernandez-Serra, Manuel Ruiz Borrego, Eva Ciruelos Gil, Javier Pascual, Montserrat Muñoz, Begoña Bermejo, Mireia Margelí, Antonio Antón-Torres, Laura Murillo, Bella Nisenbaum, Yuan Liu, Jesus Herranz, Daniel Fernandez-Garcia, Rosalía Caballero, Jose Antonio Lopez-Guerrero, Roberto Bianco, Luigi Formisano, Nicholas C Turner, Miguel Martin
CCNE1 and PLK1 mediates resistance to palbociclib in HR+/HER2- metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Javier Pascual, Juan Miguel Gil-Gil, Paula Z Proszek, Christoph C Zielinski, Alistair Reay, Manuel Ruiz Borrego, Rosalind J Cutts, Eva Ciruelos Gil, Andrew Feber, Montserrat Muñoz, Claire Swift, Begoña Bermejo, Jesus Herranz, Mireia Margelí, Antonio Antón-Torres, Zsuzsanna Kahán, Tibor Csőszi, Yuan Liu, Daniel Fernandez-Garcia, Isaac Garcia-Murillas, Michael Hubank, Nicholas C Turner, Miguel Martin
Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Laura Pons, Laura Hernández, Aintzane Urbizu, Paula Osorio, Paula Rodríguez-Martínez, Eva Castella, Ana Maria Muñoz-Marmol, Carolina Sanz, Laura Arnaldo, Eudald Felip, Vanesa Quiroga, Gustavo Tapia, Mireia Margelí, Pedro Luis Fernandez
Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer. Cancers 15 (12) (2023)
Laura Pons, Laura Hernández, Aintzane Urbizu, Paula Osorio, Paula Rodríguez-Martínez, Eva Castella, Ana Maria Muñoz-Marmol, Carolina Sanz, Laura Arnaldo, Eudald Felip, Vanesa Quiroga, Gustavo Tapia, Mireia Margelí, Pedro Luis Fernandez
Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer. Cancers 15 (12) (2023)
Angelica Ferrando-Díez, Eudald Felip, Anna Pous, Milana Bergamino Sirven, Mireia Margelí
Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. Cancers 14 (14) (2022)
Eudald Felip, Lucía Gutiérrez-Chamorro, Maica Gómez, Edurne Garcia-Vidal, Margarita Romeo Marin, Teresa Morán, Laura Layos, Laia Pérez-Roca, Eva Riveira-Muñoz, Bonaventura Clotet, Pedro Luis Fernandez, Ricard Mesía, Anna Martinez-Cardus, Ester Ballana, Mireia Margelí
Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types. Cancers 14 (3) (2022)
Marta Sant, Adrià Bernat-Peguera, Eudald Felip, Mireia Margelí
Role of ctDNA in Breast Cancer. Cancers 14 (2) (2022)